# To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy

> **NCT05410535** · PHASE4 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 431 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Patients who continued UDCA 300mg medication
- **OTHER:** Patients who discontinued UDCA 300mg prescription

## Key facts

- **NCT ID:** NCT05410535
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-15
- **Primary completion:** 2022-10-28
- **Final completion:** 2022-10-28
- **Target enrollment:** 431 (ACTUAL)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05410535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05410535, "To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05410535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*